CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction The Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non–ST-Segment Elevation Acute Coronary Syndrome SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019 Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert Panel TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial): An Observational Study to Identify Acute Heart Failure Patients at Low Risk for Rehospitalization or Mortality Epidemiology and Clinical Outcomes of Patients With Inflammatory Bowel Disease Presenting With Acute Coronary Syndrome

Original ResearchEpub January 19, 2018

JOURNAL:Am J Cardiol. Article Link

Recurrent Cardiovascular Events in Survivors of Myocardial Infarction with St-Segment Elevation (From the AMI-QUEBEC Study)

T. Huynh, M. Montigny, U. Iftikhar et al. Keywords: Acute Myocardial Infarction, Acute Coronary Syndromes, Percutaneous Coronary Intervention, Reperfusion Therapy

ABSTRACT

The characteristics and predictors of long-term recurrent ischemic cardiovascular events (RICE) following myocardial infarction with ST-segment elevation (STEMI) have not yet been clarified. We aimed to characterize the 10-year incidence, types, and predictors of RICE. We obtained 10-year follow-up of STEMI survivors at 17 Quebec hospitals in Canada (the AMI-QUEBEC Study) in 2003. There were 858 patients; mean age of 60 years and 73% males. The majority of patients receive reperfusion therapy with 53.3% and 39.2% received primary PCI and fibrinolytic therapy, respectively. Seventy-five percent of patients underwent in-hospital PCI (elective, rescue and primary). At 10-year, 42% of patients suffered a RICE with most RICEs (88%) caused by recurrent cardiac ischemia. The risk of RICE was the highest during the first year (23.5 per person-year). At 10-year, the all-cause mortality was 19.3% with one-third of deaths being RICE-related. Prior CV event, heart failure during the index STEMI hospitalization, discharge prescription of calcium-blocker increased the risk of RICE by almost two-fold. Each point increase in Thrombolysis in Myocardial Infarction (TIMI) score augmented the risk of RICE by 6% while discharge prescription of dual anti-platelets reduced the risk of RICE by 23%. Our findings suggested that survivors of STEMI remain at high long-term risk of RICE despite high rate of reperfusion therapy and in-hospital PCI. Patients with prior CV event, in-hospital heart failure and high TIMI score were particularly susceptible to RICE. Future studies are needed to confirm the impacts of calcium-blocker and dual anti-platelets on long-term risk of RICE.